Protective effect of rebamipide against celecoxib-induced gastric mucosal cell apoptosis

Tomoaki Ishihara, Ken Ichiro Tanaka, Saki Tashiro, Kosuke Yoshida, Tohru Mizushima

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

A major clinical problem encountered with the use of non-steroidal anti-inflammatory drugs (NSAIDs) is gastrointestinal complications. We have previously suggested that both decreases in prostaglandin E2 (PGE2) levels and mucosal apoptosis are involved in the development of NSAID-produced gastric lesions and that this apoptosis is mediated by an increase in the intracellular Ca2+ concentration and the resulting endoplasmic reticulum (ER) stress response and mitochondrial dysfunction. Celecoxib and rebamipide are being used clinically as a safer NSAID and an anti-ulcer drug, respectively. In this study, we have examined the effect of rebamipide on celecoxib-induced production of gastric lesions. In mice pre-administered with a low dose of indomethacin, orally administered rebamipide suppressed celecoxib-induced mucosal apoptosis and lesion production but did not decrease in PGE2 levels in the stomach. Rebamipide also suppressed celecoxib-induced increases in intracellular Ca2+ concentration, the ER stress response, mitochondrial dysfunction and apoptosis in vitro. We also found that rebamipide suppresses the increases in intracellular Ca2+ concentration induced by an activator of voltage-dependent L-type Ca2+ channels and that another blocker of this channel suppresses celecoxib-induced increases in intracellular Ca2+ concentration. These results suggest that celecoxib activates voltage-dependent L-type Ca2+ channels and that rebamipide blocks this activation, resulting in suppression of celecoxib-induced apoptosis. We believe that this novel activity of rebamipide may play an important role in the protection of gastric mucosa against the formation of celecoxib-induced lesions.

Original languageEnglish
Pages (from-to)1622-1633
Number of pages12
JournalBiochemical Pharmacology
Volume79
Issue number11
DOIs
Publication statusPublished - 2010 Jun
Externally publishedYes

Fingerprint

Celecoxib
Stomach
Apoptosis
Gastrointestinal Agents
Endoplasmic Reticulum Stress
Anti-Inflammatory Agents
Dinoprostone
Anti-Ulcer Agents
rebamipide
Electric potential
Gastric Mucosa
Indomethacin

Keywords

  • Apoptosis
  • Celecoxib
  • Rebamipide
  • Ulcer
  • Voltage-dependent L-type Ca channel

ASJC Scopus subject areas

  • Pharmacology
  • Biochemistry

Cite this

Ishihara, T., Tanaka, K. I., Tashiro, S., Yoshida, K., & Mizushima, T. (2010). Protective effect of rebamipide against celecoxib-induced gastric mucosal cell apoptosis. Biochemical Pharmacology, 79(11), 1622-1633. https://doi.org/10.1016/j.bcp.2010.01.030

Protective effect of rebamipide against celecoxib-induced gastric mucosal cell apoptosis. / Ishihara, Tomoaki; Tanaka, Ken Ichiro; Tashiro, Saki; Yoshida, Kosuke; Mizushima, Tohru.

In: Biochemical Pharmacology, Vol. 79, No. 11, 06.2010, p. 1622-1633.

Research output: Contribution to journalArticle

Ishihara, T, Tanaka, KI, Tashiro, S, Yoshida, K & Mizushima, T 2010, 'Protective effect of rebamipide against celecoxib-induced gastric mucosal cell apoptosis', Biochemical Pharmacology, vol. 79, no. 11, pp. 1622-1633. https://doi.org/10.1016/j.bcp.2010.01.030
Ishihara, Tomoaki ; Tanaka, Ken Ichiro ; Tashiro, Saki ; Yoshida, Kosuke ; Mizushima, Tohru. / Protective effect of rebamipide against celecoxib-induced gastric mucosal cell apoptosis. In: Biochemical Pharmacology. 2010 ; Vol. 79, No. 11. pp. 1622-1633.
@article{dfbf41006ec24c388fef3be9200d6e4a,
title = "Protective effect of rebamipide against celecoxib-induced gastric mucosal cell apoptosis",
abstract = "A major clinical problem encountered with the use of non-steroidal anti-inflammatory drugs (NSAIDs) is gastrointestinal complications. We have previously suggested that both decreases in prostaglandin E2 (PGE2) levels and mucosal apoptosis are involved in the development of NSAID-produced gastric lesions and that this apoptosis is mediated by an increase in the intracellular Ca2+ concentration and the resulting endoplasmic reticulum (ER) stress response and mitochondrial dysfunction. Celecoxib and rebamipide are being used clinically as a safer NSAID and an anti-ulcer drug, respectively. In this study, we have examined the effect of rebamipide on celecoxib-induced production of gastric lesions. In mice pre-administered with a low dose of indomethacin, orally administered rebamipide suppressed celecoxib-induced mucosal apoptosis and lesion production but did not decrease in PGE2 levels in the stomach. Rebamipide also suppressed celecoxib-induced increases in intracellular Ca2+ concentration, the ER stress response, mitochondrial dysfunction and apoptosis in vitro. We also found that rebamipide suppresses the increases in intracellular Ca2+ concentration induced by an activator of voltage-dependent L-type Ca2+ channels and that another blocker of this channel suppresses celecoxib-induced increases in intracellular Ca2+ concentration. These results suggest that celecoxib activates voltage-dependent L-type Ca2+ channels and that rebamipide blocks this activation, resulting in suppression of celecoxib-induced apoptosis. We believe that this novel activity of rebamipide may play an important role in the protection of gastric mucosa against the formation of celecoxib-induced lesions.",
keywords = "Apoptosis, Celecoxib, Rebamipide, Ulcer, Voltage-dependent L-type Ca channel",
author = "Tomoaki Ishihara and Tanaka, {Ken Ichiro} and Saki Tashiro and Kosuke Yoshida and Tohru Mizushima",
year = "2010",
month = "6",
doi = "10.1016/j.bcp.2010.01.030",
language = "English",
volume = "79",
pages = "1622--1633",
journal = "Biochemical Pharmacology",
issn = "0006-2952",
publisher = "Elsevier Inc.",
number = "11",

}

TY - JOUR

T1 - Protective effect of rebamipide against celecoxib-induced gastric mucosal cell apoptosis

AU - Ishihara, Tomoaki

AU - Tanaka, Ken Ichiro

AU - Tashiro, Saki

AU - Yoshida, Kosuke

AU - Mizushima, Tohru

PY - 2010/6

Y1 - 2010/6

N2 - A major clinical problem encountered with the use of non-steroidal anti-inflammatory drugs (NSAIDs) is gastrointestinal complications. We have previously suggested that both decreases in prostaglandin E2 (PGE2) levels and mucosal apoptosis are involved in the development of NSAID-produced gastric lesions and that this apoptosis is mediated by an increase in the intracellular Ca2+ concentration and the resulting endoplasmic reticulum (ER) stress response and mitochondrial dysfunction. Celecoxib and rebamipide are being used clinically as a safer NSAID and an anti-ulcer drug, respectively. In this study, we have examined the effect of rebamipide on celecoxib-induced production of gastric lesions. In mice pre-administered with a low dose of indomethacin, orally administered rebamipide suppressed celecoxib-induced mucosal apoptosis and lesion production but did not decrease in PGE2 levels in the stomach. Rebamipide also suppressed celecoxib-induced increases in intracellular Ca2+ concentration, the ER stress response, mitochondrial dysfunction and apoptosis in vitro. We also found that rebamipide suppresses the increases in intracellular Ca2+ concentration induced by an activator of voltage-dependent L-type Ca2+ channels and that another blocker of this channel suppresses celecoxib-induced increases in intracellular Ca2+ concentration. These results suggest that celecoxib activates voltage-dependent L-type Ca2+ channels and that rebamipide blocks this activation, resulting in suppression of celecoxib-induced apoptosis. We believe that this novel activity of rebamipide may play an important role in the protection of gastric mucosa against the formation of celecoxib-induced lesions.

AB - A major clinical problem encountered with the use of non-steroidal anti-inflammatory drugs (NSAIDs) is gastrointestinal complications. We have previously suggested that both decreases in prostaglandin E2 (PGE2) levels and mucosal apoptosis are involved in the development of NSAID-produced gastric lesions and that this apoptosis is mediated by an increase in the intracellular Ca2+ concentration and the resulting endoplasmic reticulum (ER) stress response and mitochondrial dysfunction. Celecoxib and rebamipide are being used clinically as a safer NSAID and an anti-ulcer drug, respectively. In this study, we have examined the effect of rebamipide on celecoxib-induced production of gastric lesions. In mice pre-administered with a low dose of indomethacin, orally administered rebamipide suppressed celecoxib-induced mucosal apoptosis and lesion production but did not decrease in PGE2 levels in the stomach. Rebamipide also suppressed celecoxib-induced increases in intracellular Ca2+ concentration, the ER stress response, mitochondrial dysfunction and apoptosis in vitro. We also found that rebamipide suppresses the increases in intracellular Ca2+ concentration induced by an activator of voltage-dependent L-type Ca2+ channels and that another blocker of this channel suppresses celecoxib-induced increases in intracellular Ca2+ concentration. These results suggest that celecoxib activates voltage-dependent L-type Ca2+ channels and that rebamipide blocks this activation, resulting in suppression of celecoxib-induced apoptosis. We believe that this novel activity of rebamipide may play an important role in the protection of gastric mucosa against the formation of celecoxib-induced lesions.

KW - Apoptosis

KW - Celecoxib

KW - Rebamipide

KW - Ulcer

KW - Voltage-dependent L-type Ca channel

UR - http://www.scopus.com/inward/record.url?scp=77950080219&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950080219&partnerID=8YFLogxK

U2 - 10.1016/j.bcp.2010.01.030

DO - 10.1016/j.bcp.2010.01.030

M3 - Article

VL - 79

SP - 1622

EP - 1633

JO - Biochemical Pharmacology

JF - Biochemical Pharmacology

SN - 0006-2952

IS - 11

ER -